Loading stock data…
NVS
$146.57-1.28 (-0.87%)
Market ClosedLast close May 1
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novartis AG in the Healthcare sector is trading at $146.57. The stock is currently 14% below its 52-week high of $170.46, remaining 9.1% above its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why NVS maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 34) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$146.57
Potential Upside
16%
Whystock Fair Value$169.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Hold
Mean target$153.87+5.0%
Range$123.00 – $180.00
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$284.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.63
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Strong income play. Yield provides a meaningful total return floor.
322.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
29.60%
Volume
Today's trading volume
995,148
Recent News
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
Here's What Analysts Are Forecasting For Novartis AG (VTX:NOVN) After Its First-Quarter Results
As you might know, Novartis AG ( VTX:NOVN ) recently reported its quarterly numbers. Revenues of US$14b were in line...
PTC Therapeutics (PTCT) Is Down 5.1% After New Votoplam Huntington’s Data And Novartis Milestone
Earlier this week, PTC Therapeutics reported positive 24‑month interim data from the PIVOT-HD extension study, showing dose-dependent slowing of Huntington’s disease progression with votoplam and a favorable long-term safety and biomarker profile versus an external natural history cohort. At the same time, Novartis’ launch of the large Phase 3 INVEST-HD trial, which triggered a US$50,000,000 milestone payment, underscores growing industry commitment to advancing votoplam toward potential...
Novartis Reshapes Growth With Biotech Deals And AI Powered R&D Push
Novartis (SWX:NOVN) is expanding its late stage pipeline through acquisitions, highlighted by the recent purchase of Avidity Biosciences. The Avidity deal brings three late stage genetic disorder therapies into the company’s portfolio at a time of industry wide patent cliffs and generic competition. Novartis is also working with Genedata on an AI native R&D data platform to support drug discovery and development productivity. For you as an investor, this combination of deal making and AI...
Novartis Expands R&D Spending Up To $70 Million Monthly After Avidity Deal
Late-stage pipeline investment rises as acquisition adds three genetic disorder therapies and trims margins by up to 2%.